REVIEW ARTICLESClusterin inhibition mediates sensitivity to chemotherapy and radiotherapy in human cancerGarcía-Aranda, Marilinaa; Téllez, Teresaa; Muñoz, Miguelb; Redondo, MaximinoaAuthor Information aDepartment of Biochemistry, REDISSEC, Hospital Costa del Sol, Marbella bResearch Laboratory of Neuropeptides, Virgen del Rocío University Hospital, Sevilla, Spain Correspondence to Maximino Redondo, MD, PhD, Department of Biochemistry, REDISSEC, Hospital Costa del Sol, Carretera de Cádiz, Km 187, 29600 Marbella, Málaga, Spain Tel: +34 951 976 773; fax: +34 952 823 219; e-mail: email@example.com Received September 9, 2016 Accepted March 25, 2017 Anti-Cancer Drugs: August 2017 - Volume 28 - Issue 7 - p 702-716 doi: 10.1097/CAD.0000000000000507 Buy Metrics Abstract Since its discovery in 1983, the protein clusterin (CLU) has been isolated from almost all human tissues and fluids and linked to the development of different physiopathological processes, including carcinogenesis and tumor progression. During the last few years, several studies have shown the cytoprotective role of secretory CLU in tumor cells, inhibiting their apoptosis and enhancing their resistance to conventional treatments including hormone depletion, chemotherapy, and radiotherapy. In an effort to determine the therapeutic potential that the inhibition of this protein could have on the development of new strategies for cancer treatment, numerous studies have been carried out in this field, with results, in most cases, satisfactory but sometimes contradictory. In this document, we summarize for the first time the current knowledge of the effects that CLU inhibition has on sensitizing tumor cells to conventional cancer treatments and discuss its importance in the development of new strategies against cancer. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.